FDA Approves Genentech's Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer - Business Wire

FDA Approves Genentech's Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer  Business Wire

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved ...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RCvH1W